Author contributions DW and NP performed experiments and collected data
Semaglutide (Wegovy) Semaglutide is a GLP-1 agonist
Similarly, in a phase II trial on lixisenatide, PD patients in the treatment group after 12 months registered a significant ( p = 0.0068) primary outcome endpoint change in motor tests, and the positive effect persisted at 2 months after discontinuation of treatment ( p 3.0.co;2-5 J
This inward clean-up effect is often touted as a reason for clearer, healthier skin
Suggested Sources & Further Reading Sikiric, P
Methods This literature screening was conducted based on the PubMed, Web of Science, and CNKI databases, with the search timeframe spanning from January 2010 to May 2025